Poseida Therapeutics, Inc. (PSTX)

NASDAQ: PSTX · IEX Real-Time Price · USD
4.70 -0.12 (-2.49%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap293.78M
Revenue (ttm)n/a
Net Income (ttm)-162.59M
Shares Out62.51M
EPS (ttm)-2.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume230,341
Open4.75
Previous Close4.82
Day's Range4.59 - 4.82
52-Week Range4.59 - 13.64
Betan/a
AnalystsStrong Buy
Price Target27.67 (+488.7%)
Earnings Daten/a

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat rel...

IndustryBiotechnology
IPO DateJul 10, 2020
CEOEric Ostertag
Employees254
Stock ExchangeNASDAQ
Ticker SymbolPSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PSTX stock is "Strong Buy." The 12-month stock price forecast is 27.67, which is an increase of 488.72% from the latest price.

Price Target
$27.67
(488.72% upside)
Analyst Consensus: Strong Buy

News

Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current Pre...

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

1 week ago - PRNewsWire

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allog...

SAN DIEGO, Dec. 20, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

1 month ago - PRNewsWire

Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the Upgrade

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematolog...

SAN DIEGO , Dec. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ...

1 month ago - PRNewsWire

Wall Street Analysts Think Poseida Therapeutics, Inc. (PSTX) Could Surge 277%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is questi...

1 month ago - Zacks Investment Research

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

2 months ago - PRNewsWire

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Societ...

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

2 months ago - PRNewsWire

Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to a 281% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

2 months ago - Zacks Investment Research

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

2 months ago - PRNewsWire

Poseida Therapeutics Announces Leadership Appointments

SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

3 months ago - PRNewsWire

A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics

Shares of Poseida Therapeutics Inc. PSTX, +1.22% were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 4502...

3 months ago - Market Watch

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

3 months ago - PRNewsWire

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting

SAN DIEGO, Oct. 1, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

3 months ago - PRNewsWire

Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors

The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that sa...

4 months ago - Benzinga

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

4 months ago - PRNewsWire

Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma

The FDA has cleared Poseida Therapeutics Inc (NASDAQ: PSTX) Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple myelo...

4 months ago - Benzinga

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic ...

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

4 months ago - PRNewsWire

New Strong Sell Stocks for August 27th

CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021

Other symbols:CDLXCYTKIVCUUUU
4 months ago - Zacks Investment Research

Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021

SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

5 months ago - PRNewsWire

Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

SAN DIEGO, July 26, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create c...

5 months ago - PRNewsWire

Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

7 months ago - PRNewsWire

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

8 months ago - PRNewsWire

Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American...

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

8 months ago - PRNewsWire

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

SAN DIEGO, May 6, 2021 /PRNewswire/ --  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create ce...

8 months ago - PRNewsWire

Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference

SAN DIEGO, May 5, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cel...

8 months ago - PRNewsWire